Top Markets
#1 BOOK OF MEME BOOK OF MEME +30.35%
#2 Geodnet Geodnet +26.04%
#3 The Black Bull The Black Bull +25.24%
#4 XPIN Network XPIN Network +23.44%
#5 EXOD EXOD +22.08%
#6 Ore Ore +21.41%
#7 Verus Coin Verus Coin +20.44%
#8 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +20.08%
#9 Neiro Neiro +19.97%
#10 ConstitutionDAO ConstitutionDAO +19.95%
Coin of the day
BOOK OF MEME BOOK OF MEME
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Classificação em ações #25241
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Preço da ação
$23.57
Última sincronização: 2026-08-20
Valor de mercado
$51.76M
Variação (1 dia)
-0.08%
Variação (1 ano)
289.59%
País
US
Negociar Apollomics, Inc. (APLM)

Categoria

Healthcare
Receita da Apollomics, Inc. (APLM)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Apollomics, Inc., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Apollomics, Inc. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US